OverviewSuggest Edit

ViewRay is a company that designs, manufactures, and markets MRIdian, an MRI-guided radiation therapy system. Its solution integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed.

TypePublic
Founded2004
HQOakwood Village, OH, US
Websiteviewray.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2019)309(+40%)
Job Openings6
Revenue (FY, 2020)$57 M(-35%)
Share Price (Sept 2021)$6.4
Cybersecurity ratingCMore

Key People/Management at ViewRay

Scott Drake

Scott Drake

President and Chief Executive Officer
Paul Ziegler

Paul Ziegler

Chief Commercial Officer
Stephen Strunk

Stephen Strunk

Vice President
James F. Dempsey

James F. Dempsey

Chief Scientific Officer
Amanda Sequira

Amanda Sequira

Senior Vice President of Clinical, Quality and Regulatory
Rob Fuchs

Rob Fuchs

Chief Human Resources Officer
Show more

ViewRay Office Locations

ViewRay has offices in Oakwood Village and Mountain View
Oakwood Village, OH, US (HQ)
2 Thermo Fisher Way
Mountain View, CA, US
815 E Middlefield Rd
Show all (2)

ViewRay Financials and Metrics

ViewRay Revenue

Embed Graph
View revenue for all periods
ViewRay's revenue was reported to be $57.02 m in FY, 2020 which is a 35% decrease from the previous period.
USD

Revenue (Q2, 2021)

15.0m

Gross profit (Q2, 2021)

(1.7m)

Gross profit margin (Q2, 2021), %

(11.1%)

Net income (Q2, 2021)

(31.0m)

EBIT (Q2, 2021)

(26.5m)

Market capitalization (14-Sept-2021)

1.0b

Closing stock price (14-Sept-2021)

6.4

Cash (30-Jun-2021)

166.9m

EV

928.8m
ViewRay's current market capitalization is $1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

81.0m87.8m57.0m

Revenue growth, %

8%(35%)

Cost of goods sold

74.4m93.3m61.1m

Gross profit

6.6m(5.5m)(4.1m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

20.3m30.2m20.9m14.3m14.2m10.1m15.5m15.0m

Cost of goods sold

25.6m26.9m20.3m16.4m15.3m11.2m15.2m16.7m

Gross profit

(5.4m)3.2m574.0k(2.1m)(1.0m)(1.1m)322.0k(1.7m)

Gross profit Margin, %

(26%)11%3%(15%)(7%)(11%)2%(11%)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

167.4m226.8m156.7m

Accounts Receivable

36.9m16.8m11.8m

Inventories

49.5m55.0m46.6m

Current Assets

277.7m311.9m224.4m
Quarterly
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(76.4m)(120.2m)(107.9m)

Depreciation and Amortization

3.5m4.7m6.4m

Inventories

(32.2m)(6.0m)8.2m

Accounts Payable

(870.0k)2.8m(3.4m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(33.4m)(64.2m)(85.0m)(27.5m)(53.7m)(81.8m)(26.7m)(57.7m)

Depreciation and Amortization

946.0k2.0m3.2m1.5m3.0m4.4m1.6m3.2m

Inventories

(15.8m)(8.8m)(10.5m)6.7m8.4m2.8m4.8m

Accounts Payable

7.0m8.3m1.2m(6.4m)(8.5m)(6.0m)(2.4m)(2.5m)
USDFY, 2018

EV/EBIT

-6.2 x

EV/CFO

-3.8 x

Revenue/Employee

366.3k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.8 x

P/E Ratio

(6.2)
Show all financial metrics

ViewRay Operating Metrics

ViewRay's Backlog was reported to be $241.3m in FY, 2020.
FY, 2018FY, 2019FY, 2020

Backlog

$212.3 m$227.3 m$241.3 m

Patent Applications (US)

252418

Patents (Foreign)

527977

Patents (US)

243038
Show all operating metrics

ViewRay Acquisitions / Subsidiaries

Company NameDateDeal Size
Vesuvius Acquisition Corp.July 23, 2015
ViewRay GmbH
ViewRay Technologies, Inc.

ViewRay Revenue Breakdown

Embed Graph

ViewRay revenue breakdown by business segment: 75.0% from Product, 24.2% from Service and 0.8% from Other

ViewRay revenue breakdown by geographic segment: 18.1% from Rest of World, 18.1% from United States, 18.1% from Rest of World, 18.1% from United States, 12.0% from Taiwan, 7.9% from France, 6.8% from United Kingdom and 0.9% from Other

ViewRay Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

ViewRay Online and Social Media Presence

Embed Graph

ViewRay News and Updates

Penn State Health Purchases Second ViewRay MRIdian® Linac

CLEVELAND, Feb. 11, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Penn State Health has purchased a second MRIdian Linac joining other pioneering institutions from around the globe investing in multiple MRIdian systems. Penn State Health's first MRIdian Linac will...

The Henry Ford Cancer Institute Installs its Second ViewRay MRIdian® Linac

CLEVELAND, Jan. 26, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Henry Ford Cancer Institute has installed its second MRIdian Linac at its new cancer pavilion, Henry Ford Cancer Institute – Detroit, which began offering patient care on January 20, 2021. Following...

ViewRay Announces Preliminary Fourth Quarter and Full Year 2020 Results

CLEVELAND, Ohio, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2020. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full...

ViewRay to Present at the 39th Annual J.P. Morgan Healthcare Conference

CLEVELAND, Dec. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Scott Drake, President and CEO, is scheduled to present at 10:50 a.m. Eastern Time on Thursday, January 14, 2021. An audio webcast...

ViewRay Reports Third Quarter 2020 Results

CLEVELAND, Nov. 5, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights: Total revenue of $10.1 million, primarily from one revenue unit, compared to $20.9 million,...

ViewRay, GenesisCare and the University of Oxford Announce Groundbreaking Compassionate Access Programme Now Open to UK Patients with Localized Pancreatic Cancer

ViewRay, Inc. (Nasdaq: VRAY) announced today that the GenesisCare Foundation's Compassionate Access Programme is now accepting patients for treatment on the MRIdian® MRI-Guided Radiation Therapy System. The program, in collaboration with the.
Show more

ViewRay Blogs

ViewRay® to Partcipate in the Cantor Global Healthcare Conference

ViewRay® to Partcipate in the Cantor Global Healthcare Conference Content Import Thu, 09/16/2021 - 16:02 ViewRay® to Partcipate in the Cantor Global Healthcare Conference 09/16/21 This release is a backfill from a News Wire General C…

ViewRay® to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

ViewRay® to Present at the Morgan Stanley 19th Annual Global Healthcare Conference Content Import Fri, 08/27/2021 - 16:02 ViewRay® to Present at the Morgan Stanley 19th Annual Global Healthcare Conference 08/27/21 This release is a backfill from a News Wire …

ViewRay Announces Equity Inducement Award under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Aug. 16, 2021 , /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced the grant of 91,240 restricted stock units to Arun Viswanath, effective August 16, 2021, as an inducement material to entering into employment with the Company as Vice President, Software

ViewRay Reports Second Quarter 2021 Results

CLEVELAND , Aug. 5, 2021 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2021 . Second Quarter 2021 Highlights Received seven new orders for MRIdian systems totaling $37.9 million , compared to four new orders

ViewRay Announces Conference Call for Second Quarter 2021 Financial Results to be Held After Market on August 5, 2021

ViewRay Announces Conference Call for Second Quarter 2021 Financial Results to be Held After Market on August 5, 2021 Content Import Thu, 07/15/2021 - 08:31 ViewRay Announces Conference Call for Second Quarter 2021 Financial Results to be Held After Market on August 5, 2021 …

GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems

Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets CLEVELAND , June 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian® MR-Guided
Show more

ViewRay Frequently Asked Questions

  • When was ViewRay founded?

    ViewRay was founded in 2004.

  • Who are ViewRay key executives?

    ViewRay's key executives are Scott Drake, Paul Ziegler and Stephen Strunk.

  • How many employees does ViewRay have?

    ViewRay has 309 employees.

  • What is ViewRay revenue?

    Latest ViewRay annual revenue is $57 m.

  • What is ViewRay revenue per employee?

    Latest ViewRay revenue per employee is $184.5 k.

  • Who are ViewRay competitors?

    Competitors of ViewRay include Varian Medical Systems, Elekta and Accuray.

  • Where is ViewRay headquarters?

    ViewRay headquarters is located at 2 Thermo Fisher Way, Oakwood Village.

  • Where are ViewRay offices?

    ViewRay has offices in Oakwood Village and Mountain View.

  • How many offices does ViewRay have?

    ViewRay has 2 offices.